We can protect your ideas and help generate benefits for you and the wider community
Protecting your ideas
MRCT protects intellectual property (IP) generated by academic researchers based in MRC Units and Institutes.
Once the commercial potential of your research has been identified, MRCT will decide how best to protect it, e.g. by applying for a patent, copyright and/or trademark. Your IP might include potential diagnostic or therapeutic products, platform technologies, medical devices, software, research reagents or know-how.
How you benefit
MRCT will seek to commercialise protected IP through, for example, licensing to an industry partner, or forming a start-up or spin-out company.
Any income generated by commercialised IP will be shared with you and your institution.
If you are employed by the MRC, you will receive this income via the Awards to Inventors scheme.
Before you publish - what you should do next
If you think your work might have some commercial potential you should speak to your Business Manager or Technology Transfer Office before you tell anyone outside your lab about it. This includes publishing a paper, or speaking about your work at a conference or with friends.
News feed
MRCT are collaborating with the University of Bristol to develop orally available small molecule TrkA antagonists for treatment of chronic intractable pain.
MRC Technology’s Therapeutic Antibody Group and The University of Aberdeen work together on project to develop therapeutic against a novel cancer target, soluble CTLA-4.
Aptuscan, a spin out company based on research carried out at the MRC Cancer Cell Unit, has been acquired by Avacta, an AIM-listed biotechnology company.
MRC Technology announced today that they have entered into an agreement with the Association for International Cancer Research (AICR) to assist in the oversight and management of intellectual property (IP) arising from AICR-funded projects.